Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Tumour Hypoxia: An Accelerator of Innate Cancer Genome Instability

FY 2014-15

Summary
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in Canadian men. Despite the numerous available therapies to combat prostate cancer, 4,000 Canadian men will inevitably die of the disease this year. With 30-40% of men destined to fail local radiotherapy or surgery, there is a clear and urgent need for both mechanistic and translational biology to understand treatment failure and improve patient outcome. All solid tumours, including prostate tumours, contain sub-regions of altered metabolism, nutrient deprivation and low oxygen. Our lab has shown that these hypoxic regions allow for cancer cell adaption and selection, ultimately driving the production of aggressive tumour phenotypes. One method in which hypoxia acts in promoting an aggressive phenotype is through its repression of the DNA damage response and repair pathway. Men who carry germline (familial) defects in their DNA repair processes, such as a mutation in the BRCA2 gene, have not only an increased risk of developing prostate cancer, but also a more aggressive form of the disease. Recent studies have suggested that 50% of prostate cancer patients whose BRCA2 gene is defective in their cancers will die within 5 years of diagnosis. We believe that the tumour microenvironment, particularly hypoxia, further adds to genetic instability and aggression within these patients with inherent DNA repair defects. We therefore have designed experiments to test the added role of hypoxia on genetic instability in BRCA2 prostate cancer models. This work forms the basis of precision cancer medicine by placing patients into different treatment response and aggression risk groups allowing for individualized treatment to improve prostate cancer survival.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331330
Name
Mahamud Osman
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Tumour Hypoxia: An Accelerator of Innate Cancer Genome Instability
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca2; Dna Repair; Genetic Instability; Hypoxia; Prostate Cancer
Abstract
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in Canadian men. Despite the numerous available therapies to combat prostate cancer, 4,000 Canadian men will inevitably die of the disease this year. With 30-40% of men destined to fail local radiotherapy or surgery, there is a clear and urgent need for both mechanistic and translational biology to understand treatment failure and improve patient outcome. All solid tumours, including prostate tumours, contain sub-regions of altered metabolism, nutrient deprivation and low oxygen. Our lab has shown that these hypoxic regions allow for cancer cell adaption and selection, ultimately driving the production of aggressive tumour phenotypes. One method in which hypoxia acts in promoting an aggressive phenotype is through its repression of the DNA damage response and repair pathway. Men who carry germline (familial) defects in their DNA repair processes, such as a mutation in the BRCA2 gene, have not only an increased risk of developing prostate cancer, but also a more aggressive form of the disease. Recent studies have suggested that 50% of prostate cancer patients whose BRCA2 gene is defective in their cancers will die within 5 years of diagnosis. We believe that the tumour microenvironment, particularly hypoxia, further adds to genetic instability and aggression within these patients with inherent DNA repair defects. We therefore have designed experiments to test the added role of hypoxia on genetic instability in BRCA2 prostate cancer models. This work forms the basis of precision cancer medicine by placing patients into different treatment response and aggression risk groups allowing for individualized treatment to improve prostate cancer survival.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mahamud, Osman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~